New combo tackles Drug-Resistant lung cancer in early trial

NCT ID NCT06106802

Recruiting now Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining two targeted drugs—lazertinib and tepotinib—can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer whose disease has worsened after initial lazertinib treatment due to MET gene changes. About 47 participants will receive daily oral doses of both drugs. The main goal is to see how many patients respond, with secondary aims including how long the benefit lasts and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lazertinib and tepotinib (two oral drugs)
What this could lead to: If successful, this combination could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to initial therapy.
What could go wrong: This is a small, early-phase trial (47 people) with no control group. The benefit may be limited to those with high MET levels, and side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER METASTATIC

Contacts and locations

Locations

Samsung Medical Center
RECRUITING

Seoul, Gangnam-gu, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.